NCT02177734
Withdrawn
Phase 1
An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age
ConditionsInfluenza
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Influenza
- Sponsor
- GlaxoSmithKline
- Primary Endpoint
- Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers
- Status
- Withdrawn
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female adults who are 18 to 60years of age (inclusive) at the time of first study vaccination.
- •Written informed consent obtained from subject.
- •Subjects who the investigator believes can and will comply with the requirements of the protocol.
- •Healthy subjects as established by medical history and physical examination.
- •Access to a consistent means of telephone contact.
- •For subjects who undergo a screening visit: Results of screening safety laboratory tests that figure in eligibility assessment must be within reference ranges before dosing.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •Female subjects of childbearing potential may be enrolled in the study, if they
- •have practiced adequate contraception for 30 days prior to vaccination, and
- •have a negative pregnancy test on the day of vaccination, and agree to continue to practice adequate contraception until 2 months after the last dose administered.
Exclusion Criteria
- •Presence or evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- •Presence or evidence of substance abuse.
- •Diagnosed with cancer, or treatment for cancer within three years.
- •Diagnosed with excessive daytime sleepiness, or narcolepsy; or history of narcolepsy in a subject's parent, sibling or child.
- •Presence of a temperature ≥ 38.0ºC (≥100.4ºF), or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
- •Receipt of systemic glucocorticoids within 30 days prior to the first dose of study vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs within 6 months of first study vaccine/ placebo dose.
- •Any significant disorder of coagulation or treatment with warfarin derivatives or heparin.
- •An acute evolving neurological disorder or Guillain Barré Syndrome within 42 days of receipt of prior seasonal or pandemic influenza vaccine.
- •Administration of an inactive vaccine within 14 days or of a live attenuated vaccine within 30 days before the first dose of study vaccine/placebo.
Outcomes
Primary Outcomes
Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers
Time Frame: At Day 42.
Occurrence of each solicited local symptom
Time Frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination.
Occurrence of each solicited general symptom
Time Frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccination.
Occurrence of clinical safety laboratory abnormalities reported for samples
Time Frame: At the Day 0, 7, 21, 28 and 42 visits.
Occurrence of unsolicited adverse events (AEs)
Time Frame: 21 days after each dose.
Occurrence of Medically Attended Adverse Events (MAEs), potential Immune Mediated Diseases (pIMDs) and Serious Adverse Events (SAEs)[Active Phase]
Time Frame: From Day 0 until Day 42.
Secondary Outcomes
- Humoral immune response in terms of vaccine homologous (H7N9) neutralizing (MN) antibody titers for each study group by age stratum (18-40 years; 41-60 years)(GMTs and Seropositivity rates at Days 0, 21, 42 and Month 6. VRR at Days 21, 42 and Month 6.)
- Occurrence of MAEs, pIMDs and SAEs(Until the Month 12 visit.)
- Evaluation of adjuvant effect as assessed by vaccine-homologous hemagglutination inhibition (HI) antibody titers(At Day 42.)
- Humoral immune response in terms of vaccine-homologous hemagglutination inhibition (HI) antibody titers for plain antigen vaccine group(At Day 42.)
- Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers.(GMTs and Seropositivity rates at Days 0, 21, 42 and Months 6 and 12. SCR and MGI at Days 21, 42 (Placebo group only) and Months 6 and 12. SPR at Days 0, 21, 42 (Placebo group only) and Months 6 and 12.)
- Humoral immune response in terms of vaccine-homologous (H7N9) neutralizing (MN) antibody titres.(GMTs and Seropositivity rates at the Days 0, 21, 42 and Month 6 visits. VRR at Days 21, 42 and Month 6 visits.)
- Humoral immune response in terms of vaccine-homologous (H7N9) HI antibody titers by age stratum.(GMTs, Seropositivity rates and SPR at Days 0, 21, 42 and Months 6 and 12. SCR and MGI at Days 21, 42 and Months 6 and 12.)
Similar Trials
Completed
Phase 1
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of AgeInfluenzaNCT01934127GlaxoSmithKline427
Completed
Phase 1
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of AgeInfluenzaNCT01999842GlaxoSmithKline424
Completed
Phase 1
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of AgeInfluenzaNCT01659086GlaxoSmithKline422
Completed
Phase 2
Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy WomenRespiratory Syncytial Virus InfectionsNCT02360475GlaxoSmithKline507
Completed
Phase 2
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and OlderInfluenzaNCT01949090GlaxoSmithKline363